NASDAQ:EGRX Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis $3.00 +0.11 (+3.63%) As of 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Eagle Pharmaceuticals Stock (NASDAQ:EGRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eagle Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.36▼$3.0050-Day Range$1.50▼$2.9052-Week Range$1.50▼$3.00Volume620 shsAverage Volume8,193 shsMarket Capitalization$38.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. Read More Eagle Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreEGRX MarketRank™: Eagle Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 653rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Eagle Pharmaceuticals. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.46% of the float of Eagle Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEagle Pharmaceuticals has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEagle Pharmaceuticals does not currently pay a dividend.Dividend GrowthEagle Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-2.29 Percentage of Shares Shorted0.46% of the float of Eagle Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEagle Pharmaceuticals has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Eagle Pharmaceuticals this week, compared to 0 articles on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eagle Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders28.90% of the stock of Eagle Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.36% of the stock of Eagle Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eagle Pharmaceuticals' insider trading history. Receive EGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EGRX Stock News HeadlinesEGRX Eagle Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comEagle Pharmaceuticals Insider Trading Activity | OTC:EGRX | BenzingaApril 28, 2025 | benzinga.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.July 3 at 2:00 AM | Porter & Company (Ad)Eagle Pharmaceuticals announces $69M pact to monetize Bendeka royaltiesApril 1, 2025 | markets.businessinsider.comEagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® RoyaltiesMarch 31, 2025 | markets.businessinsider.comEagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights PlanMarch 21, 2025 | globenewswire.comEagle Pharmaceuticals to Delist from NasdaqNovember 18, 2024 | investing.comEagle Announces Update on Delisting from Nasdaq and SEC DeregistrationNovember 15, 2024 | globenewswire.comSee More Headlines EGRX Stock Analysis - Frequently Asked Questions How have EGRX shares performed this year? Eagle Pharmaceuticals' stock was trading at $0.50 at the beginning of 2025. Since then, EGRX stock has increased by 500.0% and is now trading at $3.00. View the best growth stocks for 2025 here. How were Eagle Pharmaceuticals' earnings last quarter? Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) issued its earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to analysts' expectations of $46.70 million. How do I buy shares of Eagle Pharmaceuticals? Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eagle Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eagle Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Exxon Mobil (XOM), Advanced Micro Devices (AMD) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/09/2021Today7/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EGRX CIK827871 Webwww.eagleus.com Phone(201) 326-5300FaxN/AEmployees100Year Founded2007Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$257.55 million Price / Sales0.15 Cash Flow$7.50 per share Price / Cash Flow0.40 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares12,987,000Free Float9,234,000Market Cap$38.96 million OptionableNo Data Beta0.83 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:EGRX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.